HC Wainwright Has Positive Forecast for ACRS Q3 Earnings

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) – Research analysts at HC Wainwright raised their Q3 2025 earnings per share (EPS) estimates for shares of Aclaris Therapeutics in a report released on Wednesday, May 14th. HC Wainwright analyst R. Selvaraju now forecasts that the biotechnology company will post earnings per share of ($0.14) for the quarter, up from their prior estimate of ($0.17). HC Wainwright currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for Aclaris Therapeutics’ current full-year earnings is ($0.82) per share. HC Wainwright also issued estimates for Aclaris Therapeutics’ Q4 2025 earnings at ($0.16) EPS and FY2025 earnings at ($0.56) EPS.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.07. Aclaris Therapeutics had a negative return on equity of 40.26% and a negative net margin of 136.65%.

A number of other research analysts also recently issued reports on the company. Scotiabank cut their price target on Aclaris Therapeutics from $15.00 to $9.00 and set a “sector outperform” rating on the stock in a report on Friday, May 9th. StockNews.com downgraded Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 8th. Finally, Cantor Fitzgerald assumed coverage on Aclaris Therapeutics in a research note on Tuesday, March 18th. They set an “overweight” rating on the stock. One research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $10.00.

Aclaris Therapeutics Trading Up 7.4%

Shares of NASDAQ:ACRS opened at $1.31 on Friday. Aclaris Therapeutics has a 12-month low of $0.95 and a 12-month high of $5.17. The business’s fifty day simple moving average is $1.36 and its 200-day simple moving average is $2.23. The company has a market capitalization of $141.85 million, a PE ratio of -2.52 and a beta of 0.42.

Institutional Trading of Aclaris Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Adage Capital Partners GP L.L.C. acquired a new stake in Aclaris Therapeutics during the 4th quarter worth about $23,876,000. Vivo Capital LLC acquired a new stake in Aclaris Therapeutics during the 4th quarter worth about $22,044,000. Rock Springs Capital Management LP lifted its position in Aclaris Therapeutics by 125.3% during the 4th quarter. Rock Springs Capital Management LP now owns 6,204,309 shares of the biotechnology company’s stock worth $15,387,000 after acquiring an additional 3,450,814 shares during the period. RA Capital Management L.P. acquired a new stake in Aclaris Therapeutics during the 4th quarter worth about $11,573,000. Finally, Millennium Management LLC lifted its position in Aclaris Therapeutics by 111.0% during the 1st quarter. Millennium Management LLC now owns 4,134,148 shares of the biotechnology company’s stock worth $6,325,000 after acquiring an additional 2,175,101 shares during the period. Institutional investors and hedge funds own 98.34% of the company’s stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.